(19)

(12)





(11) EP 4 356 903 A1

EUROPEAN PATENT APPLICATION

(43) Date of publication: 24.04.2024 Bulletin 2024/17

Europäisches Patentamt European Patent Office Office européen des brevets

- (21) Application number: 23204447.9
- (22) Date of filing: 18.10.2023
- (84) Designated Contracting States:
 AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR Designated Extension States:
 BA Designated Validation States:
 KH MA MD TN
- (30) Priority: 19.10.2022 TR 202215877
- (71) Applicant: SANOVEL ILAC SANAYI VE TICARET A.S. Istanbul 34460 (TR)
- (72) Inventors:SUNEL, Fatih
 - Istanbul (TR)

A61K 9/20 (2006.01) A61K 9/48 (2006.01) A61K 9/28 (2006.01) A61K 31/4439 (2006.01) (52) Cooperative Patent Classification (CPC):

(52) Cooperative Patent Classification (CPC): A61K 9/2072; A61K 9/2846; A61K 9/2886; A61K 9/4858; A61K 31/4439

(51) International Patent Classification (IPC):

- BILGEHAN ATAK, Fadime Istanbul (TR)
 ATAMAN, Seval Istanbul (TR)
 YAZICI, Ozlem
- Istanbul (TR)
 SARP, Onder Istanbul (TR)
- (74) Representative: Sevinç, Erkan
 Istanbul Patent A.S.
 Plaza-33, Büyükdere Cad. No: 33/16
 Sisli
 34381 Istanbul (TR)

(54) MICROTABLETS COMPRISING LANSOPRAZOLE

(57) The present invention relates to pharmaceutical composition in the form of capsule having enteric coating microtablets comprising lansoprazole wherein microtablets further comprising at least one surfactant, at least one pH modifier and further at least other pharmaceuti-

cally excipient and wherein enteric coating comprising metacrylic acid copolymer dispersion. The capsule is obtained by a process which is free of solvent, the process is simple, rapid, cost effective, time-saving and industrially convenient process.

Processed by Luminess, 75001 PARIS (FR)

Description

Field of the invention

⁵ **[0001]** The present invention relates to pharmaceutical composition in the form of capsule having enteric coating microtablets comprising lansoprazole wherein microtablets further comprising at least one surfactant, at least one pH modifier and further at least other pharmaceutically excipient and wherein enteric coating comprising metacrylic acid copolymer dispersion. The capsule is obtained by a process which is free of solvent, the process is simple, rapid, cost effective, time-saving and industrially convenient process.

Background of the invention

[0002] Lansoprazole, chemical name 2-(((3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl)methyl) sulfinyl)-1H-benzoyl Imidazole, brownish white crystalline powder, easily soluble in dimethylamide, soluble in methanol, insoluble in ethanol and ether, almost insoluble in water. It has a chemical structure which is shown in the Formula I.




10

15



50



Formula I

[0004] Lansoprazole is extremely unstable under acidic conditions, and is degraded to inactive components in a short time under low pH environment, so it is easily degraded in gastric acid environment. In order to improve the bioavailability of the drug, it needs to be prepared as an enteric-coated preparation.

³⁵ **[0005]** Chinese Patent Application No.: 201010245689.6 discloses a lansoprazole enteric capsule formulation and preparation method, using sodium bicarbonate as a stabilizer, cross-linked polyvinylpyrrolidone as a disintegrant, and acrylic resin as an enteric coating agent.

[0006] U.S. Patent No. 6,328,994 discloses an orally disintegrable lansoprazole tablet which comprises fine enteric coated granules having an average particle diameter of $400 \mu \pi L$ or less.

⁴⁰ **[0007]** Therefore, it is still necessary to prepare the lansoprazole enteric-coated capsule that a kind of related substance content is low, the desired stability and is suitable for industrialized production.

Detailed description of the Invention

⁴⁵ **[0008]** The main object of the present invention is to eliminate problems caused by active substance and bringing additional advantages to the relevant prior art. To explain in more detail, the main purpose is to provide a pharmaceutical composition in the form of capsule having enteric coating microtablets having high physical and chemical stability and a long shelf life by the help of selection of excipients.

[0009] Another object of the present invention is to obtain a pharmaceutical composition in the form of capsule having enteric coating microtablets providing improved dissolution profile, it also is cost effective.

[0010] Another object of the present invention is to obtain a pharmaceutical composition in the form of capsule having enteric coating microtablets providing improved excellent pharmacomechanic properties, such as flowability, compressibility and content uniformity.

[0011] In particular, there is a need to combine an acid-labile physiologically active substance, with basic inorganic salts and so forth for stability, and further to coat with coating layers such as an enteric layer. It is an important problem to produce a small enteric coated microtablets, even though it contains the acid-labile physiologically active substance in small content. In this invention, a pharmaceutical composition in the form of capsule having enteric coating microtablets is used. The composition provides the desired stability and the desired profile. Also, microtablets have content uniformity

and flowability.

10

15

20

[0012] The microtablets are cylindrical with a flat or convex upper side and lower side and with a diameter and height which are preferably approximately equal and, independently of one another, preferably have a tablet size of from about 1 mm to about 5 mm, more preferably from about 1.5 mm to about 4.5 mm. The microtablets have a tablet weight of

- ⁵ about 1 mg to about 50 mg. Preferably, the microtablets have a tablet weight of about 2 mg to about 35 mg.
 [0013] According to one embodiment of the present invention, a pharmaceutical composition in the form of capsule having enteric coating microtablets comprising lansoprazole wherein;
 - Microtablets comprising at least one surfactant, at least one pH modifier and further at least other pharmaceutically
 excipient,
 - Enteric coating comprising methacrylic acid copolymer dispersion.

[0014] An enteric coating protects the lansoprazole in microtablet from the acidic environment of the stomach, permitting it to be released in the higher pH environment of the lower GI tract. So, enteric coating provides to release the active ingredient gradually and predictably over a 12-hour to 24-hour period.

- **[0015]** The methacrylic acid copolymer is used alone or in combination with other another enteric polymers to achieve the desired delayed release profile. It also helps to provide stability. Especially, Methacrylic Acid-Ethyl Acrylate Copolymer (1:1) Type A is used.
 - **[0016]** According to one embodiment of the present invention, using Ph modifier ensures that lansoprazole, which is unstable at low pH, remains at the desired stability under long conditions.
- **[0017]** According to one embodiment of the present invention, the amount of lansoprazole is between 3.0 % and 20.0% by weight in the total composition. Preferably, the amount of lansoprazole is between 5.0 % and 13.0% by weight in the total composition.
- [0018] Suitable surfactants are selected from the group comprising sodium dodecyl sulphate, sodium lauryl sulfate, cetylpyridinium chloride, docusate sodium, lauric acid, polyoxyethylene sorbitan fatty acid esters (polysorbate), phospholipids, cetrimide or mixtures thereof.

[0019] According to one embodiment of the present invention, the surfactant is sodium dodecyl sulphate. It is a synthetic organic compound widely used in pharmaceutical products as an anionic surfactant. In the present invention, it provides the desired profile. It also helps to provide flowability.

³⁰ **[0020]** According to one embodiment of the present invention, the amount of surfactant is between 0.1 % and 3.0% by weight in the total composition.

[0021] Suitable pH modifiers are selected from the group comprising magnesium carbonate, aluminum potassium sulfate, anhydrous citric acid, anhydrous disodium hydrogen phosphate, potassium carbonate, anhydrous sodium dihydrogen phosphate, dibasic potassium sulfate, calcium carbonate, dilute hydrochloric acid, monobasic potassium phos-

³⁵ phate, phosphoric acid, adipic acid, sodium acetate, sodium bicarbonate, sodium carbonate, sodium citrate, sodium dihydrogen phosphate dihydrate, tribasic sodium phosphate or mixtures thereof.

[0022] According to one embodiment of the present invention, the pH modifier is magnesium carbonate.

[0023] According to one embodiment of the present invention, the amount of pH modifier is between 1.0 % and 8.0% by weight in the total composition.

⁴⁰ **[0024]** According to one embodiment of the present invention, the microtablets comprise further at least one pharmaceutically acceptable excipient which is selected from the group comprising diluents, disintegrants, binders, lubricants, glidants or mixtures thereof.

[0025] Suitable diluents are selected from the group comprising microcrystalline cellulose, mannitol, lactose monohydrate, spray-dried mannitol, lactose, starch, dextrose, sucrose, fructose, maltose, sorbitol, xylitol, inositol, kaolin, inorganic

- salts, calcium salts, polysaccharides, dicalcium phosphate, sodium chloride, dextrates, lactitol, maltodextrin, sucrose-maltodextrin mixture, trehalose, sodium carbonate, sodium bicarbonate, calcium carbonate or mixtures thereof.
 [0026] According to one embodiment of the present invention, the diluent is microcrystalline cellulose or mannitol or
 - lactose monohydrate or mixtures thereof.
 - **[0027]** According to one embodiment of the present invention, the diluent is microcrystalline cellulose.
- 50 [0028] According to one embodiment of the present invention, the diluent is mannitol and lactose monohydrate. [0029] According to one embodiment of the present invention, the amount of diluents is between 30.0 % and 75.0% by weight in the total composition. Preferably, the amount of diluents is between 40.0 % and 60.0% by weight in the total composition. The amount provides the desired content uniformity. Since the amount of active ingredient is low compared to the whole composition, it is important to ensure content uniformity.
- ⁵⁵ **[0030]** Suitable disintegrants are selected from the group comprising croscarmellose sodium, crospovidone, alginic acid, alginates, ion-exchange resins, magnesium aluminium silica, sodium carboxymethyl cellulose, calcium silicate, sodium starch glycolate, carboxymethyl cellulose, calcium carboxymethyl cellulose, docusate sodium, guar gum, low substituted hydroxypropyl cellulose, polyacryline potassium, poloxamer, povidone, sodium alginate, sodium glycine

carbonate, or mixtures thereof.

5

15

30

45

[0031] According to one embodiment of the present invention, the disintegrant is croscarmellose sodium or crospovidone or mixtures thereof.

- **[0032]** According to one embodiment of the present invention, the amount of disintegrant is between 1.0 % and 8.0% by weight in the total composition.
- **[0033]** Suitable binders are selected from the group comprising hydroxypropyl cellulose, polyvinylpyrrolidone, natural gums, gelatin, collagen, agar, alginates, co-povidone, sodium alginate, gum, guar gum, starch mucilage, acacia mucilage, bentonite, laponit, cetostearyl alcohol, pullulan, polydextrose, polyethylene oxide, pectin, aluminia hydroxide, hyaluronic acid or mixtures thereof.
- ¹⁰ **[0034]** According to one embodiment of the present invention, the binder is hydroxypropyl cellulose or polyvinylpyrrolidone or mixtures thereof.

[0035] According to one embodiment of the present invention, the amount of binder is between 0.1 % and 5.0% by weight in the total composition.

- **[0036]** Suitable glidants are selected from the group comprising talc, colloidal silica anhydrous, colloidal silicon dioxide, calcium silicate, aluminium silicate, magnesium silicate, magnesium oxide, starch or mixtures thereof.
- **[0037]** According to one embodiment of the present invention, the glidant is talc or colloidal silica anhydrous or mixtures thereof. Using these glidants provides the flowability.
- **[0038]** According to one embodiment of the present invention, the amount of glidant is between 0.1 % and 9.0% by weight in the total composition.
- 20 [0039] Suitable lubricants are selected from the group comprising magnesium stearate, silica, calcium stearate, stearic acid, polyethylene glycol, sodium stearyl fumarate, sodium lauryl sulfate, magnesium lauryl sulfate, fumaric acid, glyceryl palmito sulfate, hydrogenated vegetable oil, zinc stearate or mixtures thereof.

[0040] According to one embodiment of the present invention, the lubricant is magnesium stearate.

[0041] According to one embodiment of the present invention, the amount of lubricant is between 0.4 % and 3.0% by weight in the total composition.

[0042] According to one embodiment of the present invention, microtablets comprises;

- Lansoprazole
- Mannitol
- Magnesium carbonate
 - Lactose monohydrate
 - HPC
 - Sodium dodecyl sulphate
- ³⁵ **[0043]** According to one embodiment of the present invention, microtablets comprises;
 - Lansoprazole
 - Microcrystalline cellulose pH 112
 - Magnesium carbonate
- 40 PVP K-30
 - Sodium dodecyl sulphate
 - Crospovidon CL

[0044] According to one embodiment of the present invention, the enteric coating comprises;

- Metacrylic acid copolymer dispersion,
- Sodium hydroxide,
- Polysorbate 80.
- ⁵⁰ **[0045]** However, lansoprazole is unstable and prone to impurities. In addition to affecting the efficacy of drugs, impurities may increase the risk of toxic and side effects. In this invention, to eliminate this problem, a process which is free of solvent is preferred in terms of the desired stability. In using process, lansoprazole is not exposed to moisture and solvents. Thanks to this way eliminates the problems stability of lansoprazole and provides additional advantages to the relevant field of art.
- ⁵⁵ **[0046]** According to one embodiment of the present invention, the microtablets are obtained by a process which is free of solvent.

[0047] The present invention is to obtain stable microtablets which is obtained by dry granulation or direct compression with improved stability.

Example 1: Microtablets are obtained by direct compression

[0048]

5

10

15

Ingredients	Amount (% by weight of the total formulation)
Lansoprazole	3.0 - 15.0
Mannitol	40.0 - 57.0
Magnesium carbonate	1.0 - 8.0
Lactose monohydrate	1.0 - 8.0
HPC	0.1 - 5.0
Sodium dodecyl sulphate	0.1 - 3.0
Croscarmellose sodium	1.0 - 8.0
Talc	0.1 - 4.5
Colloidal silica anhydrous	0.1 - 4.5
Magnesium stearate	0.4 - 3.0
Microtablet	
Enteric coating	10.0 -30.0
Total Enteric coating microtablet	100

25

20

Example 2: Microtablets are obtained by direct compression

[0049]

30	Ingredients	Amount (% by weight of the total formulation)		
	Lansoprazole	8.5		
	Mannitol	49.2		
35	Magnesium carbonate	3.1		
	Lactose monohydrate	3.7		
	HPC	0.7		
40	Sodium dodecyl sulphate	0.7		
	Croscarmellose sodium	3.0		
	Talc	3.90		
	Colloidal silica anhydrous	3.90		
45	Magnesium stearate	1.30		
	Microtablet			
	Enteric coating	22		
50	Total Enteric coating microtablet	100		

50

55

[0050] A process for example 1 or 2;

a) Mixing Lansoprazole, Mannitol, Magnesium carbonate, Lactose monoydrate, HPC, Sodium dodecyl sulphate, croscarmellose sodium, colloidal silica, talc for 15 minutes,

b) Adding weighed and 0.6 mm sieved Magnesium stearate to dry mixture and mix for 3 minutes,

c) Obtaining microtablets,

d) Coating the microtablets with enteric coating having Metacrylic acid copolymer dispersion,

e) Filling the microtablets into capsules.

Example 3: Microtablets are obtained by dry granulation

[0051]

5

10

15

20

Ingredients	Amount (% by weight of the total formulation)
Lansoprazole	3.0-15.0
Microcrystalline cellulose pH 112	40.0 - 65.0
Magnesium carbonate	1.0 -8.0
PVP K-30	0.1 - 5.0
Sodium dodecyl sulphate	0.1 - 3.0
Crospovidon CL	1.0 - 8.0
Colloidal silica anhydrous	0.1 - 3.0
Magnesium stearate	0.4 - 3.0
Microtablet	
Enteric coating	10.0 -30.0
Total Enteric coating microtablet	100

25

30

35

40

45

55

Example 4: Microtablets are obtained by dry granulation

[0052]

Ingredients	Amount (% by weight of the total formulation)
Lansoprazole	8.5
Microcrystalline cellulose pH 112	56.13
Magnesium carbonate	3.97
PVP K-30	3.40
Sodium dodecyl sulphate	0.99
Crospovidon CL	3.97
Colloidal silica anhydrous	0.57
Magnesium stearate	0.57
Microtablet	
Enteric coating	21.9
Total Enteric coating microtablet	100

⁵⁰ **[0053]** A process for example 3 or 4;

a) Mixing Lansoprazole, a half of MCC pH 112, colloidal silicon dioxide, PVP K-30, magnesium carbonate, sodium dodecyl sulphate for 10 minutes,

b) Adding weighed and 0.6 mm sieved a half of Magnesium stearate to dry mixture and mix for 3 minutes,

- c) Performing slug granulation in compactor,
 - d) Sieving dry granules into 1.2 mm,

e) Adding the other half of MCC pH 112, Crospovidon CL and then mixing for 5 minutes,

f) Adding 0.6mm sieved the other half of Mg-stearate and mixing for 3 minutes,

g) Obtaining microtablets,

h) Coating the microtablets with enteric coating having Metacrylic acid copolymer dispersion,

i) Filling the microtablets into capsules.

5

Enteric coating

[0054]

10

15

Ingredients	
Metacrylic acid copolymer di	spersion
Sodium hydroxide	
Polysorbate 80	
Propilen glikol	
Titanium dioxide	
Cetyl alcohol	

20

Claims

- A pharmaceutical composition in the form of capsule having enteric coating microtablets comprising lansoprazole wherein;
 - Microtablets comprising at least one surfactant, at least one pH modifier and further at least other pharmaceutically excipient,
- 30
- Enteric coating comprising methacrylic acid copolymer dispersion.
- 2. The pharmaceutical composition according to claim 1, wherein surfactants are selected from the group comprising sodium dodecyl sulphate, sodium lauryl sulfate, cetylpyridinium chloride, docusate sodium, lauric acid, polyoxyethylene sorbitan fatty acid esters (polysorbate), phospholipids, cetrimide or mixtures thereof.
- ³⁵ **3.** The pharmaceutical composition according to claim 1, wherein the surfactant is sodium dodecyl sulphate.
 - 4. The pharmaceutical composition according to claim 1, wherein pH modifiers are selected from the group comprising magnesium carbonate, aluminum potassium sulfate, anhydrous citric acid, anhydrous disodium hydrogen phosphate, potassium carbonate, anhydrous sodium dihydrogen phosphate, dibasic potassium sulfate, calcium carbon-
- 40 ate, dilute hydrochloric acid, monobasic potassium phosphate, phosphoric acid, adipic acid, sodium acetate, sodium bicarbonate, sodium carbonate, sodium citrate, sodium dihydrogen phosphate dihydrate, tribasic sodium phosphate or mixtures thereof.
 - 5. The pharmaceutical composition according to claim 1, wherein the pH modifier is magnesium carbonate.
 - 6. The pharmaceutical composition according to claim 1, wherein the microtablets comprise further at least one pharmaceutically acceptable excipient which is selected from the group comprising diluents, disintegrants, binders, lubricants, glidants or mixtures thereof.
- ⁵⁰ 7. The pharmaceutical composition according to claim 6, wherein diluents are selected from the group comprising microcrystalline cellulose, mannitol, lactose monohydrate, spray-dried mannitol, lactose, starch, dextrose, sucrose, fructose, maltose, sorbitol, xylitol, inositol, kaolin, inorganic salts, calcium salts, polysaccharides, dicalcium phosphate, sodium chloride, dextrates, lactitol, maltodextrin, sucrose-maltodextrin mixture, trehalose, sodium carbonate, sodium bicarbonate, calcium carbonate or mixtures thereof.
- 55

45

8. The pharmaceutical composition according to claim 7, wherein the diluent is microcrystalline cellulose or mannitol or lactose monohydrate or mixtures thereof.

- **9.** The pharmaceutical composition according to claim 8, wherein the amount of diluents is between 30.0 % and 75.0% by weight in the total composition.
- 10. The pharmaceutical composition according to claim 6, wherein disintegrants are selected from the group comprising croscarmellose sodium, crospovidone, alginic acid, alginates, ion-exchange resins, magnesium aluminium silica, sodium carboxymethyl cellulose, calcium silicate, sodium starch glycolate, carboxymethyl cellulose, calcium carboxymethyl cellulose, docusate sodium, guar gum, low substituted hydroxypropyl cellulose, polyacryline potassium, poloxamer, povidone, sodium alginate, sodium glycine carbonate, or mixtures thereof.
- 10 11. The pharmaceutical composition according to claim 6, wherein binders are selected from the group comprising hydroxypropyl cellulose, polyvinylpyrrolidone, natural gums, gelatin, collagen, agar, alginates, co-povidone, sodium alginate, gum, guar gum, starch mucilage, acacia mucilage, bentonite, laponit, cetostearyl alcohol, pullulan, polydextrose, polyethylene oxide, pectin, aluminia hydroxide, hyaluronic acid or mixtures thereof.
- **12.** The pharmaceutical composition according to claim 11, wherein the binder is hydroxypropyl cellulose or polyvinylpyrrolidone or mixtures thereof.
 - 13. The pharmaceutical composition according to claim 6, wherein glidants are selected from the group comprising talc, colloidal silica anhydrous, colloidal silicon dioxide, calcium silicate, aluminium silicate, magnesium silicate, magnesium oxide, starch or mixtures thereof.
 - 14. The pharmaceutical composition according to claim 1, wherein the enteric coating comprises;
 - Metacrylic acid copolymer dispersion,
 - Sodium hydroxide,
 - Polysorbate 80.
 - **15.** The pharmaceutical composition according to claim 1, wherein the microtablets are obtained by a process which is free of solvent.

8

30

20

25

5

35

45

50

55



EUROPEAN SEARCH REPORT

Application Number

EP 23 20 4447

Category	Citation of document with indica		Relevant	CLASSIFICATION OF THE
	of relevant passages		to claim	APPLICATION (IPC)
x	KR 2020 0097564 A (YUH	IAN CORP [KR])	1,2,4,	INV.
	19 August 2020 (2020-0	8-19)	6-13	A61K9/20
Y	* example 2 *		1-15	A61K9/28
				A61K9/48
x	US 2008/214619 A1 (WOL		1,4,6-13	A61K31/4439
	AL) 4 September 2008 (2008–09–04)		
Y	* table 11 *		1–15	
	* example 12 *			
	* paragraph [0298] *			
x	CN 112 716 917 A (JIAN	G HATSONG)	1,4-6,	
4	30 April 2021 (2021-04		10-13	
Y	* examples 4-7 *		1-15	
-				
x	US 2013/216617 A1 (ROY	SUNILENDU BHUSHAN	1,4-7,	
	[IN] ET AL) 22 August	2013 (2013-08-22)	11-13	
Y	* example 2 *		1–15	
Y	KR 2019 0092805 A (SAM		1–15	
	[KR]) 8 August 2019 (2	019-08-08)		TECHNICAL FIELDS
	* example 7 * * table 7 *			SEARCHED (IPC)
	* paragraph [0045] *			A61K
	* paragraph [0050] *			
Y	US 2015/072015 A1 (NAG	AHARA NAOKI [JP] ET	1–15	
	AL) 12 March 2015 (201	.5-03-12)		
	* example 9 *			
	* table 8 *			
	The present search report has been	drawn up for all claims		
1	Place of search	Date of completion of the search		Examiner
C01)	Munich	20 February 2024		
CORM 1503 03.322 (P04C01) Lad : X 200 : 0 Pot : 0 C				del, Ulrike
3.82 ·	ATEGORY OF CITED DOCUMENTS	T : theory or principle E : earlier patent doc	underlying the in ument, but publis	nvention shed on, or
8 X:par	icularly relevant if taken alone icularly relevant if combined with another	after the filing date D : document cited in)	
un i pa⊓				
doc	ument of the same category nological background	L : document cited for		

5

ANNEX TO THE EUROPEAN SEARCH REPORT ON EUROPEAN PATENT APPLICATION NO.

EP 23 20 4447

5

This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report. The members are as contained in the European Patent Office EDP file on The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

20-02-2024

15	10		Patent document ted in search report		Publication date		Patent family member(s)		Publication date
15 CA 2663090 A1 07-02-2008 20 US 2008016837 A2 17-06-2009 20 CN 112716917 A 30-04-2021 NONE 00-09-2008 21 US 2013216617 A1 22-08-2013 US 2013216617 A1 22-08-2013 25 KR 20190092805 A 08-08-2019 NONE 08-08-2019 NONE 26 KR 20190092805 A 08-08-2019 NONE 08-08-2019 NONE 30 US 2015072015 A1 12-03-2015 CA 2599340 A1 31-08-2006 CA 30 EP 1652100 A1 07-11-2017 EP 2275088 A2 19-01-2011 ES 2550626 T3 11-11-2017 EP 2275088 A2 30 US 2015072015 A1 12-03-2015 CA 2599340 A1 31-08-2006 CA 30 US 2015072015 A1 12-03-2015 CA 2599340 A1 31-08-2006 US 2008138427 A1 31 US 2005072015 A1 12-03-2015 US 2005072015 A1 24-07-2008 US 2006090845 A1 24-07-2008 US 2006090845 A1 35 US 2005172015 A1 12-03-2015 WO 2006090845 A1 31-08-2006 US 2006090845 A1 31-08-2006 US 2006090845 A1 40 US 2015072015 A1 13-08-2006 US 2006090845 A1 31-08-2006 US 2006090845 A1 31-08-2006 US 2006090845 A1 50 US		KF	20200097564	A	19-08-2020	NONE	E		
15 CA 2663090 A1 07-02-2008 20 US 200821619 A1 04-09-2008 20 CN 112716917 A 30-04-2021 NONE 04-09-2008 21 US 2013216617 A1 22-08-2013 US 2013216617 A1 22-08-2013 25 KR 20190092805 A 08-08-2019 NONE 05-01-2012 26 KR 20190092805 A 08-08-2019 NONE 05-01-2012 26 KR 20190092805 A 08-08-2019 NONE 05-01-2012 27 KR 20190092805 A 08-08-2019 NONE 08-08-2016 CA 2599340 A1 31-08-2006 CA 30 US 2015072015 A1 12-03-2015 CA 2599340 A1 31-08-2006 CA 2764881 A1 31-08-2006 CA 30 US 2015072015 A1 12-03-2015 CA 2599340 A1 31-08-2006 CA 2764881 A1 31-08-2006 CA 30 US 2015072015 A1 12-03-2013 US 200813827 A1 12-06-2008 US 200813827 A1 12-06-2008 US 31 US 2006090845 A1 31-08-2006 US US 2006090845 A1 31-08-2006 US 2006090845 A1 31-08-2006 US 40 US 2006090845 A1 31-08-2006 US US 2006090845 A1 31-08-2005 US		 US	2008214619	A1	04-09-2008	AU	2007281224	A1	07-02-2008
EP 2068854 A1 17-06-2009 04-09-2008 20 CN 112716917 A 30-04-2021 NONE US 2013216617 A1 22-08-2013 US 2013216617 A1 22-08-2013 25 RR 20190092805 A 08-08-2019 NONE 30 RR 20190092805 A 08-08-2019 NONE 30 S 2015072015 A1 12-03-2015 CA 2599340 A1 31-08-2006 30 FR 20190092805 A 08-08-2019 NONE CA 2794881 A1 31-08-2006 30 FR 20190092805 A 08-08-2019 NONE CA 2794881 A1 31-08-2006 30 FS S 2015072015 A1 12-03-2015 CA 2599340 A1 31-08-2006 30 FS S 2015072015 A1 12-03-2013 JP 5124267 B2 23-01-2013 31 JP S02006090845 A1 32-08-2006 US 2006090845 A1 20-06-2008	15								
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $									
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $									
25 US 2013216617 A1 22-08-2013 US 2013216617 A1 22-08-2013 25 KR 20190092805 A 08-08-2019 NONE	20	 CN	112716917	A					
wo 2012001705 A2 05-01-2012 25 KR 20190092805 A 08-08-2019 NONE US 2015072015 A1 12-03-2015 CA 2599340 A1 31-08-2006 30 EP 1852100 A1 07-11-2007 30 ES 267581 T3 11-11-2015 30 ES 267581 T3 11-07-2018 31 T T T 30 T T T 30 ES 267581 T3 11-07-2018 31 T T T 32 T T T 33 T T T 34 T T T 35 T T T 36 T T T 37 T		 US	 2013216617	 A1					
25 US 2015072015 A1 12-03-2015 CA 2599340 A1 31-08-2006 EP 1852100 A1 07-11-2007 EP 2275088 A2 19-01-2011 ES 255062 G T3 11-11-2015 ES 250502 G T3 11-11-2015 ES 2675581 T3 11-07-2018 JP 5378465 B2 25-12-2013 JP 95378465 B2 25-12-2013 JP 2011235172 A 24-11-2011 JP W02006090845 A1 24-07-2008 US 2008138427 A1 12-06-2008 US 2006090845 A1 31-08-2006 40 45 50 50 50 50 50 50 50 50 50 5									
30 CA 2784881 A1 31-08-2006 EP 1852100 A1 07-11-2007 EP 2757088 A2 19-01-2011 ES 2550626 T3 11-11-2015 ES 2675581 T3 11-07-2018 JP 5124267 B2 23-01-2013 JP 5378465 E2 25-12-2013 JP 802006090845 A1 24-07-2008 US 2008138427 A1 12-06-2008 US 2015072015 A1 12-06-2008 US 2015072015 A1 12-03-2015 WO 2006090845 A1 31-08-2006 40 45 50	25	 KF	20190092805	A	08-08-2019	NONE	 C		
30 CA 2784881 A1 31-08-2006 EP 1852100 A1 07-11-2007 EP 2757088 A2 19-01-2011 ES 2550626 T3 11-11-2015 ES 2675581 T3 11-07-2018 JP 5124267 B2 23-01-2013 JP 5378465 E2 25-12-2013 JP 802006090845 A1 24-07-2008 US 2008138427 A1 12-06-2008 US 2015072015 A1 12-06-2008 US 2015072015 A1 12-03-2015 WO 2006090845 A1 31-08-2006 40 45 50		 US	2015072015	 A1	12-03-2015	CA	2599340	 A1	31-08-2006
30 EP 1852100 A1 07-11-2007 EP 2275088 A2 19-01-2011 ES 2275088 A2 19-01-2013 JP 5124267 B2 23-01-2013 JP 5124267 B2 23-01-2013 JP 201235172 A 24-11-2011 JP 201235172 A 24-11-2011 JP 201235172 A 24-07-2008 US 2008138427 A1 12-06-2008 US 2015072015 A1 13-06-2006 WO 2006090845 A1 31-08-2006									
30 30 30 30 30 35 50 55 55 55 55 55 55 55 55 5									
30 ES 2550626 T3 11-11-2015 ES 2675581 T3 11-07-2018 JP 5178465 B2 25-12-2013 JP 2011235172 A 24-11-2011 JP 2008138427 A1 12-06-2008 US 2006090845 A1 24-07-2008 US 2016072015 A1 12-06-2008 US 2016090845 A1 31-08-2006 40									
ES 2675581 T3 11-07-2018 JP 5124267 B2 23-01-2013 JP 2011235172 A 24-11-2011 JP 2011235172 A 14-11-2011 JP W02006090845 A1 24-07-2008 US 2008138427 A1 12-06-2008 US 2015072015 A1 12-03-2015 WO 2006090845 A1 31-08-2006 50 50 50 50 50	30								
JP 5124267 B2 23-01-2013 JP 5378465 B2 25-12-2013 JP 2011235172 A 24-11-2011 JP 201338427 A1 12-06-2008 US 2015072015 A1 12-03-2015 WO 2006090845 A1 31-08-2006 40									
35 JP 5378465 B2 25-12-2013 JP 2011235172 A 24-11-2011 JP W02006090845 A1 24-07-2008 US 2015072015 A1 12-03-2015 WO 2006090845 A1 31-08-2006									
35 JP W02006090845 A1 24-07-2008 US 2008138427 A1 12-06-2008 US 2015072015 A1 12-03-2015 WO 2006090845 A1 31-08-2006									
50 US 2008138427 A1 12-06-2008 US 2015072015 A1 12-03-2015 WO 2006090845 A1 31-08-2006 40 45 50 50 50						JP	2011235172	A	24-11-2011
40 55	25					JP V	02006090845	A1	24-07-2008
wo 2006090845 A1 31-08-2006 40	30					US	2008138427	A1	12-06-2008
40 45 50 55						US	2015072015	A1	12-03-2015
45 50 see 40 55 see 40						WO	2006090845	A1	31-08-2006
50 55 85	40								
50 55 85									
50 55 85									
55 Y	45								
55 Y									
55 Y									
55 Y									
	50								
		459							
		RM P0							
	55	6							

REFERENCES CITED IN THE DESCRIPTION

This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.

Patent documents cited in the description

• CN 201010245689 [0005]

• US 6328994 B [0006]

Non-patent literature cited in the description

• Takeda Corporation of Japan after omeprazole. Japan's Takeda Pharmaceutical Co., Ltd. and Houde Company, 1992 [0003]